(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Receipt of the Drug Clinical Trial Approval Notice
Filed with SSE · Stock code 600276 · · 2 pages · Chinese
Summary by 6ix AI
The approval was granted by the National Medical Products Administration, allowing the company to commence clinical trials shortly.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Jiangsu Hengrui Pharmaceuticals Co., Ltd. on 6ix
Story so far
Earlier from Jiangsu Hengrui Pharmaceuticals
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on Acceptance by the EMA of the Application for Drug Marketing Authorization
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Progress in Repurchasing A-Shares
- Jiangsu Hengrui Pharmaceuticals: Hengrui Pharma Announces EMA Validation of Marketing Authorisation Application for Wevdury (fuzuloparib) in Combination with Abiraterone for Metastatic Castration-Resistant Prostate Cancer
- Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
Follow Jiangsu Hengrui Pharmaceuticals into a list and get an email when it puts out news.
Follow Jiangsu Hengrui Pharmaceuticals